Aigen Investment Management LP Makes New $2 Million Investment in BioNTech SE Sponsored ADR $BNTX

Aigen Investment Management LP purchased a new position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 20,988 shares of the company’s stock, valued at approximately $1,998,000.

Other hedge funds also recently bought and sold shares of the company. Larson Financial Group LLC lifted its position in shares of BioNTech by 86.4% in the fourth quarter. Larson Financial Group LLC now owns 274 shares of the company’s stock valued at $26,000 after acquiring an additional 127 shares in the last quarter. Caitong International Asset Management Co. Ltd lifted its position in shares of BioNTech by 520.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 310 shares of the company’s stock valued at $30,000 after acquiring an additional 260 shares in the last quarter. Huntington National Bank lifted its position in shares of BioNTech by 1,266.7% in the third quarter. Huntington National Bank now owns 410 shares of the company’s stock valued at $40,000 after acquiring an additional 380 shares in the last quarter. Tower Research Capital LLC TRC lifted its position in shares of BioNTech by 118.2% in the second quarter. Tower Research Capital LLC TRC now owns 563 shares of the company’s stock valued at $60,000 after acquiring an additional 305 shares in the last quarter. Finally, Jones Financial Companies Lllp lifted its position in shares of BioNTech by 50.6% in the third quarter. Jones Financial Companies Lllp now owns 1,199 shares of the company’s stock valued at $118,000 after acquiring an additional 403 shares in the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

Insider Activity at BioNTech

In related news, COO Sierk Poetting sold 50,000 shares of the stock in a transaction that occurred on Wednesday, April 22nd. The stock was sold at an average price of $110.56, for a total value of $5,528,000.00. Following the completion of the sale, the chief operating officer owned 399,387 shares of the company’s stock, valued at approximately $44,156,226.72. This trade represents a 11.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 19.20% of the company’s stock.

BioNTech Price Performance

NASDAQ:BNTX opened at $90.54 on Friday. BioNTech SE Sponsored ADR has a one year low of $79.52 and a one year high of $124.00. The company has a debt-to-equity ratio of 0.01, a quick ratio of 8.74 and a current ratio of 8.80. The stock has a market cap of $22.90 billion, a PE ratio of -15.40 and a beta of 1.32. The stock has a 50 day moving average price of $94.57 and a 200 day moving average price of $98.47.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Saturday, February 14th. The company reported ($0.39) EPS for the quarter. BioNTech had a negative net margin of 44.39% and a negative return on equity of 5.30%. The company had revenue of $1.06 billion during the quarter. Equities research analysts expect that BioNTech SE Sponsored ADR will post -4.66 EPS for the current fiscal year.

BioNTech announced that its board has approved a stock repurchase plan on Thursday, May 7th that authorizes the company to repurchase $1.00 billion in shares. This repurchase authorization authorizes the company to reacquire up to 4.2% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its shares are undervalued.

Analyst Ratings Changes

BNTX has been the topic of several research reports. Wells Fargo & Company decreased their target price on BioNTech from $150.00 to $140.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 6th. BMO Capital Markets decreased their target price on BioNTech from $143.00 to $128.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 11th. Canaccord Genuity Group decreased their target price on BioNTech from $171.00 to $158.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. The Goldman Sachs Group restated a “buy” rating on shares of BioNTech in a research report on Wednesday, March 11th. Finally, Citigroup decreased their target price on BioNTech from $145.00 to $130.00 and set a “buy” rating on the stock in a research report on Wednesday, March 11th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $129.56.

BioNTech Company Profile

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.